Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...